Active substanceLetrozoleLetrozole
Similar drugsTo uncover
  • Lestrodex
    pills inwards 
  • Letrosa®
    pills inwards 
    ANSTAR, AG     Switzerland
  • Letrozole
    pills inwards 
    APF-TRADING, CJSC     Russia
  • Letrozole
    pills inwards 
    JODAS EKSPOIM, LLC     Russia
  • Letrozole
    pills inwards 
  • Letrozole
    pills inwards 
    Kern Pharma S.L.     Spain
  • Letrozole
    pills inwards 
  • Letrozole
    pills inwards 
  • Letrozole-Teva
    pills inwards 
    TEVA, LLC     Russia
  • Letrosan
    pills inwards 
  • Letrotera
    pills inwards 
  • Loreta
    pills inwards 
  • Nexazole®
    pills inwards 
    GEDEON RICHTER, OJSC     Hungary
  • Oreta®
    pills inwards 
  • Femara®
    pills inwards 
    Novartis Pharma AG     Switzerland
  • Extrasia
    pills inwards 
    VEROPHARM SA     Russia
  • Estrolet®
    pills inwards 
    NATIVA, LLC     Russia
  • Dosage form: & nbspfilm coated tablets
    Composition:

    1 tablet, film-coated, contains:

    active substance: letrozole - 2.50 mg;

    auxiliary substances: lactose monohydrate - 84.70 mg, cellulose microcrystalline 19.00 mg, corn starch - 20.90 mg,Povidone-K30 (polyvinylpyrrolidone-K30) 2.00 mg, silicon dioxide colloid 1.50 mg, talc 2.80 mg, magnesium stearate -1.40 mg, sodium carboxymethyl starch 6.40 mg, iron oxide color yellow - 0.70 mg;

    shell: talcum - 0.12 mg, hypromellose-E5 - 1.75 mg, macrogol-6000 - 0.35 mg, titanium dioxide-0.50 mg, iron-oxide oxide yellow-0.09 mg.

    Description:

    Round, biconvex tablets, covered with a film membrane, yellow.

    Pharmacotherapeutic group:Antitumor agent, estrogen synthesis inhibitor
    ATX: & nbsp

    L.02.B.G.04   Letrozole

    L.02.B.G   Enzyme Inhibitors

    Pharmacodynamics:

    Letrozole has an antiestrogenic effect, selectively inhibits aromatase (an enzyme for the synthesis of estrogens) by highly competitive binding to the subunit of this enzyme, the heme cytochrome P450. It blocks the synthesis of estrogens in both peripheral and tumor tissues.

    In postmenopausal women, estrogens are formed predominantly when the aromatase enzyme that converts androgen synthesized in the adrenal gland (primarily androstenedione and testosterone) into estrone and estradiol. Daily intake of letrozole in a daily dose of 0.1-5 mg leads to a decrease in the concentration of estradiol,estrone and estrone sulfate in blood plasma at 75-95% of the original content. Suppression of the synthesis of estrogens is maintained throughout the treatment period.

    With the use of letrozole in the dose range from 0.1 to 5 mg, there is no violation of the synthesis of steroid hormones in the adrenal glands; test with ACTH does not reveal violations of the synthesis of aldosterone or cortisol. Additional appointment of glucocorticoids and mineralocorticoids is not required.

    The blockade of the biosynthesis of estrogens does not lead to the accumulation of androgens, which are precursors of estrogens. Against the background of the use of letrozole, there were no changes in the concentrations of luteinizing and follicle-stimulating hormones in the blood plasma, changes in the thyroid function, changes in the lipid profile, an increase in the frequency of myocardial infarction and strokes.

    Against the background of treatment with letrozole, the incidence of osteoporosis is slightly increased (6.9% compared with 5.5% on placebo). However, the incidence of bone fractures in patients receiving letrozole, does not differ from that of healthy people of the same age.

    Adjuvant therapy with letrozole early stages of breast cancer reduces the risk of relapse, increases the disease-free survival for 5 years, reduces the risk of developing secondary tumors.

    With prolonged adjuvant therapy letrozol reduces the risk of relapse by 42%. A significant advantage over the disease-free survival in the letrozole group was noted regardless of the involvement of the lymph nodes. Treatment with letrozole reduces the mortality of patients with lymph node involvement by 40%.

    Pharmacokinetics:

    Letrozole is quickly and completely absorbed from the gastrointestinal tract (GIT), the average bioavailability is 99.9%. Food intake slightly reduces the absorption rate. The mean time to reach the maximum concentration of letrozole in the blood (TSmOh) is 1 hour when taking letrozole on an empty stomach and 2 hours - when taken with food; the mean value of the maximum concentration (CmOh) is 129 ± 20.3 nmol / l when taken on an empty stomach and 98.7 ± 18.6 nmol / l - when taken with food, however, the degree of absorption of letrozole (when estimating the area under the curve "concentration-time" (AUC)) does not change.

    Small changes in the rate of absorption are regarded as having no clinical significance, so letrozole can be taken regardless of food intake.

    The connection of letrozole with proteins blood plasma is approximately 60% (the predominant albumin is 55%). The concentration of letrozole in erythrocytes is about 80% of that in blood plasma. The apparent volume of distribution in the equilibrium state is about 1.87 ± 0.47 l / kg. The equilibrium concentration is achieved within 2-6 weeks of daily intake of a daily dose 2.5 mg. Pharmacokinetics is nonlinear. Cumulation with long-term use is not noted.

    Letrozole is largely metabolized by isozymes CYP3A4 and CYP2A6 cytochrome P450 with formation pharmacologically inactive carbinol compound.

    It is excreted mainly by kidneys in the form of metabolites, to a lesser extent - through the intestine. The final half-life (T1 / 2) is 48h.

    The pharmacokinetic parameters of letrozole do not depend on the age of the patient.

    In renal failure pharmacokinetic parameters do not change.

    With a mild violation of liver function (Child-Pugh B) mean values AUC although higher by 37%, but remain within the range of values ​​that are observed / in persons without violations of liver function. In patients with cirrhosis of the liver and severe impairment of its function (Child-Pugh FROM) AUC increases by 95% and T1 / 2 by 187%.However, given the good tolerability of high doses of the drug (5-10 mg / day) in these cases, there is no need to change the dose of letrozole.
    Indications:

    Early stages of breast cancer, cells of which have receptors for hormones, in postmenopausal women as adjuvant therapy.

    Early stages of breast cancer in postmenopausal women after completion of standard adjuvant tamoxifen therapy, as extended adjuvant therapy.

    Common hormone-dependent forms of breast cancer in postmenopausal women (first-line therapy).

    Common forms of breast cancer in postmenopausal women (natural or induced artificially) who received previous therapy with antiestrogens.

    Contraindications:

    Hypersensitivity to letrozole or any other component of the drug.

    Endocrine status characteristic of the reproductive period.

    Pregnancy, the period of breastfeeding.

    Children's age (effectiveness and safety for children not established).

    Carefully:

    There is no data on the use of letrozole in patients with creatinine clearance less than 10 ml / min.Before prescribing letrozole, such patients should carefully weigh the relationship between the potential risk and the expected effect of the treatment.

    Dosing and Administration:

    Inside, regardless of food intake.

    Adults: The recommended dose of Lethrosan is 2.5 mg once daily, daily, and for a long time.

    As an extended adjuvant therapy treatment should last for 5 years (no longer than 5 years).

    When signs appear, the progression of the disease, the use of Lethrosan should be stopped.

    In elderly patients, dose adjustment of Lethrosan is not required. Patients with impaired hepatic and / or renal function: with violations of the liver or kidneys (creatinine clearance> 10 ml / min), dose adjustment is not required. Nevertheless, with severe disorders, liver function (on a scale Child-Pugh C) Patients should be under constant supervision.

    Side effects:

    As a rule, adverse reactions were mild or moderate and mainly related to suppression of the synthesis of estrogens.

    The incidence of adverse reactions is estimated as follows: arising "very often" -> 10%, "often" -1-10%, "sometimes" - 0.1-1%, "rarely" - 0.01-1.1% , "very rarely" - <0.01%, including individual messages.

    On the part of the digestive system: often - nausea, vomiting, indigestion / constipation, diarrhea; sometimes abdominal pain, stomatitis, dry mouth, increased activity of "liver" enzymes.

    From the nervous system: often - headache, dizziness, depression; sometimes - anxiety, nervousness, irritability, drowsiness, insomnia, memory impairment, dysesthesia, paresthesia, hypesthesia, eating disorders, episodes of cerebral circulation disorders.

    From the hematopoiesis: sometimes - a leukopenia.

    From the cardiovascular system: sometimes - heart palpitations, tachycardia, thrombophlebitis of the superficial and deep veins, increased blood pressure (BP), ischemic heart disease (angina, myocardial infarction, cardiac insufficiency), thromboembolism; rarely - embolism of the pulmonary artery, thrombosis of the arteries, stroke.

    From the respiratory system: sometimes - shortness of breath, cough.

    From the skin and skin appendages: often - alopecia, excessive sweating, skin rash, (including erythematous, maculopapular, vesicular rash, psoriasis-like rashes); sometimes itching, dry skin, urticaria; highly rarely - angioedema, anaphylactic reactions.

    From the musculoskeletal system: very often - arthralgia; often - myalgia, pains in bones, osteoporosis, fractures of bones, sometimes - arthritis.

    From the sense organs: sometimes - cataract, eye irritation, "blurring" of vision, a violation of taste sensations.

    From the side of the urinary system: sometimes - frequent urination of urinary tract infection.

    On the part of the reproductive system: sometimes - vaginal bleeding, vaginal discharge, vaginal dryness, pain in the mammary glands.

    Other: very often - paroxysmal sensations of heat ("hot flashes"); often - increased fatigue, asthenia, malaise, peripheral edema, increase body weight, hypercholesterolemia, anorexia, increased appetite; sometimes - weight loss, thirst, hyperthermia (pyrexia), dry mucous membranes, generalized edema, pain in tumor foci.

    Overdose:

    There are separate reports of cases of dozethozin overdose. No specific methods of treatment of overdose are known. Symptomatic and supportive therapy is indicated. Letrozole is removed from the plasma by hemodialysis.

    Interaction:

    With concomitant administration of letrozole with cimetidine and warfarin, clinically significant interactions are not observed.

    Clinical experience in the application of letrozole in combination with other antitumour agents is currently not available.

    According to the research results in vitro letrozole suppresses activity of cytochrome P450 isoenzymes - CYP2A6 and CYP2C19 (the latter is moderately). When deciding the importance of these data for the clinic, it is necessary to take into account that the isoenzyme CYP2A6 does not play a significant role in the metabolism of drugs. In experiments in vitro it was shown that letrozole in concentrations 100 times higher than the equilibrium values ​​in plasma, does not have the ability to significantly suppress the metabolism of diazepam (a substrate for CYP2C19). Thus, clinically Significant interactions with the isoenzyme CYP2C19 are unlikely. Nevertheless, caution should be exercised in the combined use of letrozole and drugs metabolized predominantly with the abovementioned isozymes and having a narrow therapeutic index .
    Special instructions:

    Patients with severe impairment of liver function should be under constant supervision.

    In time of letrozole therapy, given the potential for pregnancy, women in the perimenopausal and early postmenopausal period should use reliable contraceptive methods before establishing a stable postmenopausal hormone level.

    Effect on the ability to drive transp. cf. and fur:

    Some side effects of the drug, such as general weakness and dizziness, can affect the ability to perform potentially hazardous activities, requiring concentration of attention and quick reactions. In this regard, care should be taken when driving vehicles and machinery.

    Form release / dosage:

    Tablets, film-coated 2.5 mg.

    Packaging:

    10 tablets per blister, made of PVC and aluminum foil.

    For 3 blisters together with instructions for use are placed in a cardboard box.

    Storage conditions:

    In a dry, protected from light place at a temperature of no higher than 25 ° C. Keep out of the reach of children.

    Shelf life:

    3 years.

    Do not use after the expiry date printed on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:LP-000827
    Date of registration:07.10.2011
    The owner of the registration certificate:San Pharmaceutical Industries Co., Ltd.San Pharmaceutical Industries Co., Ltd. India
    Manufacturer: & nbsp
    Representation: & nbspSAN PHARMACEUTICAL INDUSTRIES LTD. SAN PHARMACEUTICAL INDUSTRIES LTD. India
    Information update date: & nbsp20.10.2015
    Illustrated instructions
      Instructions
      Up